Drug Trial Radar · NCT00144781
A Dose-optimization Study of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I (MPS I) Disease
Last checked: Nov 20, 2026Latest source record: Apr 3, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
34
Actual
Start
Dec 2004
Primary completion
Jan 2006
Study completion Jan 2006
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- BioMarin/Genzyme LLC
- First posted
- Sep 5, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to evaluate differences in the pharmacodynamic response of 4 Aldurazyme® (laronidase) dose regimens in patients with Mucopolysaccharidosis I (MPS I).
Conditions
- Mucopolysaccharidosis I
- Hurler's Syndrome
- Hurler-Scheie Syndrome
- Scheie Syndrome
Interventions
Aldurazyme (Recombinant Human Alpha-L-Iduronidase)Biological
0.58 mg/kg every week
Aldurazyme (Recombinant Human Alpha-L-Iduronidase)Biological
1.2 mg/kg every week
Aldurazyme (Recombinant Human Alpha-L-Iduronidase)Biological
1.2 mg/kg every other week
Aldurazyme (Recombinant Human Alpha-L-Iduronidase)Biological
1.8 mg/kg every other week
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline to Week 26 in Urinary Glycosaminoglycan (GAG) LevelTime frame: Baseline to 26 Weeks
Locations
5 sites in 2 countries. Site status is shown where the registry gives one.
Universidade Federal de Minas Gerais
Belo Horizonte, Brazil
Hospital de Clinical de Porto Alegre
Porto Alegre, Brazil
Universidade Federal de Sao Paulo
São Paulo, Brazil
Hospital Infantil Joana de Gusmao
Florianópolis, Santa Catarina, Brazil
Division of Clinical and Metabolic Genetics
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.